dc.contributor.author | Eren, Zehra | |
dc.contributor.author | Günal, Mehmet Yalçın | |
dc.contributor.author | Arı Bakır, Elif | |
dc.contributor.author | Çoban, Jale | |
dc.contributor.author | Çaglayan, Berrak | |
dc.contributor.author | Ekimci, Nur | |
dc.contributor.author | Ethemoğlu, Sinem | |
dc.contributor.author | Albayrak, Özgür | |
dc.contributor.author | Akdeniz, Tuba | |
dc.contributor.author | Yanıkkaya Demirel, Gülderen | |
dc.contributor.author | Kılıç, Ertugrul | |
dc.contributor.author | Kantarcı, Gülçin | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T20:01:35Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T20:01:35Z | |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Eren, Z., Günal, M. Y., Arı Bakır, E., Çoban, J., Çaglayan, B., Ekimci, N. ... Kantarcı, G. (2014). Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats. Kidney and Blood Pressure Research, 39(6), 581-590. https://dx.doi.org/10.1159/000368471 | en_US |
dc.identifier.issn | 1420-4096 | |
dc.identifier.issn | 1423-0143 | |
dc.identifier.uri | https://dx.doi.org/10.1159/000368471 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/3357 | |
dc.description | WOS: 000347728100009 | en_US |
dc.description | PubMed ID: 25532067 | en_US |
dc.description.abstract | Background/Aims: The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats. Methods: Forty male Sprague Dawley rats were divided into 5 groups of 8 rats each, namely the control (Group C), diabetes (Group D), aliskiren (Group A), paricalcitol (Group P), and aliskiren plus paricalcitol (Group A+P) groups. Aliskiren was given by oral-gavage at a dose of 50 mg/kg/day once daily for 12 weeks. Paricalcitol was given by intraperitoneally at a dose of 0,4 mu g/kg/three day of week for 12 weeks. Renal function parameters, oxidative stress biomarkers, mRNA expression of renin-angiotensin system parameters and kidney histology were determined. Results: Group A+P had lower mean albumin-to-creatinine ratio (ACR) (p=0.004) as well as higher creatinine clearance (CCr) (p<0.005) than the diabetic rats (Group D). Combination therapy significantly increased CCr (Group A+P vs Group A, p<0.005; Group A+P vs Group P, p=0.022) and reduced ACR (Group A+P vs Group A, p=0.018; Group A+P vs Group P, p<0.005) when compared to monotherapy. Serum malondialdehyde levels were significantly lower (p=0.004); glutathion levels (p=0.003), glutathion peroxidase (p=0.004) and superoxide dismutase (p<0.005) activities were significantly higher in group A+P than in group D. The mean scores of mRNA expression of renin (p<0.005), angiotensin II (p=0.012) and angiotensin type 1 receptor (p=0.018) in group A+P were significantly lower. Although combination therapy showed no additional effect on oxidative system, renin-angiotensin system and renal histology, aliskiren plus paricalcitol significantly decreased interstitial fibrosis volume when compared to monotherapy (Group A+P vs Group A, p<0.005; Group A+P vs Group P, p=0.002). Conclusion: Our data seem to suggest a potential role of aliskiren plus paricalcitol acting synergystically for reducing the progression of diabetic nephropathy in an experimental rat model. | en_US |
dc.description.sponsorship | Scientific and Technical Research Council of Turkey [TUBITAK 111S299] | en_US |
dc.description.sponsorship | This work was supported by The Scientific and Technical Research Council of Turkey (TUBITAKTUBITAK SBAG 111S299). The authors would like to acknowledge the contributions of Prof. Dr. Mujdat Uysal. We thank Burak Caglayan and Mustafa Caglar Beker for expert technical assistance. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Karger | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Attribution-NonCommercial 3.0 Unported | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | * |
dc.subject | Aliskiren | en_US |
dc.subject | Diabetic Nephropathy | en_US |
dc.subject | Paricalcitol | en_US |
dc.title | Effects of paricalcitol and aliskiren combination therapy on experimental diabetic nephropathy model in rats | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Kidney and Blood Pressure Research | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Fizyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-6494-8923 | en_US |
dc.identifier.volume | 39 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.startpage | 581 | en_US |
dc.identifier.endpage | 590 | en_US |
dc.relation.tubitak | info:eu-repo/grantAgreement/TUBITAK/SOBAG/111S299 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1159/000368471 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q2 | en_US |